Table 2.
Association between baseline IL-6 levels and patient characteristics.
| Characteristic | IL-6 Low (n = 36) |
IL-6 High (n = 22) |
p-Value |
|---|---|---|---|
| Age | |||
| Median (range), y | 61 (39–82) | 59 (47–83) | 0.572 |
| ≥65, n (%) | 13 (36.1) | 10 (45.5) | 0.480 |
| Male, n (%) | 28 (77.8) | 14 (63.6) | 0.242 |
| ECOG performance status | 0.316 | ||
| 0 | 16 (44.4) | 6 (27.3) | |
| 1 | 17 (47.2) | 12 (54.5) | |
| 2 | 3 (8.3) | 4 (18.2) | |
| IMDC prognostic risk, n (%) | 0.009 | ||
| Favorable | 9 (25.0) | 2 (9.1) | |
| Intermediate | 21 (58.3) | 8 (36.4) | |
| Poor | 6 (16.7) | 12 (54.5) | |
| Pathology, n (%) | 0.356 | ||
| Clear cell | 27 (75.0) | 14 (63.6) | |
| Non-clear cell | 9 (25.0) | 8 (36.4) | |
| No. of organs with metastases, n (%) | 0.366 | ||
| 0, 1 | 14 (38.9) | 6 (27.3) | |
| ≥2 | 22 (61.1) | 16 (72.7) | |
| Sites of metastasis, n (%) | |||
| Lung | 28 (77.8) | 19 (86.4) | 0.418 |
| Lymph node | 7 (19.4) | 10 (45.5) | 0.035 |
| Bone | 9 (25.0) | 12 (54.5) | 0.023 |
| Liver | 4 (11.1) | 2 (9.1) | 0.806 |
| Previous nephrectomy, n (%) | 28 (53.8) | 2 (33.3) | 0.018 |